Spotlight on AKT: Current Therapeutic Challenges
Authors:
- 12 March 2020
- journal article
- editorial
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (3) , 225-227
Abstract
The protein kinase B (Akt) exemplifies an important switch of cell death and survival within the PI3K/Akt signaling pathway, which renders Akt a valuable target in diseases such as cancer. Herein, we give a short overview of clinical applications involving Akt, outline promising and innovative approaches to investigate the role of this kinase in diseases, and highlight the current challenges that require thorough investigation to set the groundwork for successful therapeutic strategies.Keywords
Funding Information
- Studienstiftung des Deutschen Volkes
This publication has 15 references indexed in Scilit:
- Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐SelectivityAngewandte Chemie International Edition, 2019
- Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationBreast Cancer Research, 2019
- First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinomaAmerican Journal of Medical Genetics Part A, 2019
- AKT Inhibition in Solid Tumors With AKT1 MutationsJournal of Clinical Oncology, 2017
- AKT in cancer: new molecular insights and advances in drug developmentBritish Journal of Clinical Pharmacology, 2016
- Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)International Journal of Oncology, 2015
- Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092PLOS ONE, 2015
- A kinase-independent function of AKT promotes cancer cell survivaleLife, 2014
- Circumventing Cancer Drug Resistance in the Era of Personalized MedicineCancer Discovery, 2012
- Akt signalling in health and diseaseCellular Signalling, 2011